Zobrazeno 1 - 10
of 846
pro vyhledávání: ''
Autor:
Hervé Tilly, Gilles Salles, Wolfram Klapper, Stephan Stilgenbauer, Martin Dreyling, Christian Schmidt, Michael Unterhalt, Pierre Feugier, Eva Hoster, Christiane Pott, Josée M. Zijlstra, Lothar Kanz, Jan Walewski, Vincent Ribrag, Michal Szymczyk, Jeanette K. Doorduijn, Olivier Hermine, Marek Trneny, Christian H. Geisler, Florian Kaiser, Hanneke C. Kluin-Nelemans, Catherine Thieblemont
Publikováno v:
Journal of Clinical Oncology, 38(3), 248-256. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 38(3), 248-+. American Society of Clinical Oncology
Kluin-Nelemans, H C, Hoster, E, Hermine, O, Walewski, J, Geisler, C H, Trneny, M, Stilgenbauer, S, Kaiser, F, Doorduijn, J K, Salles, G, Szymczyk, M, Tilly, H, Kanz, L, Schmidt, C, Feugier, P, Thieblemont, C, Zijlstra, J M, Ribrag, V, Klapper, W, Pott, C, Unterhalt, M & Dreyling, M H 2020, ' Treatment of Older Patients With Mantle Cell Lymphoma (MCL) : Long-Term Follow-Up of the Randomized European MCL Elderly Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 3, pp. 248-256 . https://doi.org/10.1200/JCO.19.01294
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(3), 248-256. American Society of Clinical Oncology
Journal of Clinical Oncology, 38(3), 248-+. American Society of Clinical Oncology
Kluin-Nelemans, H C, Hoster, E, Hermine, O, Walewski, J, Geisler, C H, Trneny, M, Stilgenbauer, S, Kaiser, F, Doorduijn, J K, Salles, G, Szymczyk, M, Tilly, H, Kanz, L, Schmidt, C, Feugier, P, Thieblemont, C, Zijlstra, J M, Ribrag, V, Klapper, W, Pott, C, Unterhalt, M & Dreyling, M H 2020, ' Treatment of Older Patients With Mantle Cell Lymphoma (MCL) : Long-Term Follow-Up of the Randomized European MCL Elderly Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 3, pp. 248-256 . https://doi.org/10.1200/JCO.19.01294
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(3), 248-256. American Society of Clinical Oncology
PURPOSE In an update of the randomized, open-label, phase III European Mantle Cell Lymphoma (MCL) Elderly trial (ClinicalTrials.gov identifier: NCT00209209 ), published in 2012, we aimed to confirm results on long-term outcome focusing on efficacy an
Autor:
Massimo Aglietta, Tomislav Dragovich, Sara Lonardi, Michael J. Overman, Jean-Marie Ledeine, Usman Shah, Dana Backlund Cardin, Alain Hendlisz, Eric Van Cutsem, J. Gricar, María Luisa Limón, Sandzhar Abdullaev, Bart Neyns, Gabriele Luppi, Ka Yeung Mark Wong, Pilar García-Alfonso, Heinz-Josef Lenz
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(2)
PURPOSE Nivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) that p
Autor:
Steven P. Treon, Jeffrey Matous, Meletios A. Dimopoulos, Ramón García-Sanz, Leonard T. Heffner, Jerry Ping, M. Lia Palomba, Veronique Leblond, Israel Arango-Hisijara, B. Hauns, Christian Buske, David MacDonald, Alessandra Tedeschi, Charles Herbaux, Chaim Shustik, Beatrice Mahe, Marzia Varettoni, Judith Trotman, Constantine S. Tam, Efstathios Kastritis
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, ⟨10.1200/JCO.21.00838⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, ⟨10.1200/JCO.21.00838⟩
[Purpose]: The double-blind, randomized, placebo-controlled phase III iNNOVATE study showed sustained efficacy of ibrutinib-rituximab in Waldenström's macroglobulinemia (WM). Here, we present the final analysis from iNNOVATE. [Methods]: Patients had
Autor:
Suresh S. Ramalingam, Lei He, Mária Szilasi, Martin Dunbar, Bruce A. Bach, Ramaswamy Govindan, Julien Mazieres, Silvia Novello, R. Bernabé, Xin Huang, Everett E. Vokes, Peter Ansell, Salih Zeki Guclu, Dmitry Bentsion, Philip Clingan, Zanete Zvirbule, Jair Bar, Vasudha Sehgal, Konstantinos N. Syrigos, Jaimee Glasgow, Lauren Averett Byers
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(32)
PURPOSE Squamous non–small-cell lung cancer (sqNSCLC) is genetically complex with evidence of DNA damage. This phase III study investigated the efficacy and safety of poly (ADP-ribose) polymerase inhibitor veliparib in combination with conventional
Autor:
Annette Juul Vangsted, Abdullah A. Masud, Jeremy A. Ross, Simon J. Harrison, Shir-Jing Ho, Torben Plesner, Hang Quach, Nizar J. Bahlis, Rachid Baz, Orlando F. Bueno, Sheryl Coppola, Xiaoqing Yang, Simon D. J. Gibbs, Jonathan L. Kaufman, Philippe Moreau
Publikováno v:
Bahlis, N J, Baz, R, Harrison, S J, Quach, H, Ho, S J, Vangsted, A J, Plesner, T, Moreau, P, Gibbs, S D, Coppola, S, Yang, X, Al Masud, A, Ross, J A, Bueno, O & Kaufman, J L 2021, ' Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14) ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 39, no. 32, pp. 3602-3612 . https://doi.org/10.1200/JCO.21.00443
PURPOSE Venetoclax is an oral BCL-2 inhibitor with single-agent activity in patients with relapsed or refractory multiple myeloma (RRMM) with t(11;14) translocation. Venetoclax efficacy in RRMM may be potentiated through combination with agents inclu
Autor:
Wenfeng Fang, Zhixiong Lin, Chong Zhao, Quanlie Yang, Yan Huang, Jun Jia, Jiewen Peng, Shixiu Wu, Yaxiong Zhang, Mingjun Xu, Conghua Xie, Rensheng Wang, Jianji Pan, Xiaozhong Chen, Yunpeng Yang, Peijian Peng, Xiaolong Cao, Xuping Xi, Jianping Xiong, Qin Lin, Xuan Wu, Yingni Lian, Jin-Gao Li, Xiaojun Lu, Li Zhang, Zhihua Li, Qing Lin, Gengsheng Yu, Dongping Chen, Shaodong Hong
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(29)
PURPOSEGEM20110714 (ClinicalTrials.gov identifier: NCT01528618 ), the first randomized, phase III study of systemic chemotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC), reported significant progression-free survival improvement wit
Autor:
Peter A. Kaufman, Ellis G. Levine, Richard Piekarz, Karen L. Smith, Joseph A. Sparano, Bryan A. Faller, Alexandra Thomas, Kathy D. Miller, Ursa Brown-Glaberman, Roisin M. Connolly, Jane B. Trepel, Fengmin Zhao, George Thomas Budd, Adedayo A. Onitilo, Mark E. Burkard, Min-Jung Lee, Jennifer S. Winn, Antonio C. Wolff, Melanie Royce
Publikováno v:
J Clin Oncol
PURPOSE Endocrine therapy resistance in advanced breast cancer remains a significant clinical problem that may be overcome with the use of histone deacetylase inhibitors such as entinostat. The ENCORE301 phase II study reported improvement in progres
Autor:
Jamal Misleh, Olwen Hahn, Dean F. Bajorin, Karla A Ballman, Joel Picus, Michael J. Morris, Scott T. Tagawa, Walter M. Stadler, Susan Halabi, Jonathan E. Rosenberg, Benjamin A. Teply, Christopher Sweeney, Daniel A. Vaena, Robert Dreicer, Eric J. Small, Christopher J. Hoimes, Sreedhar Katragadda, Elizabeth R. Plimack, Pamela J. Atherton, Thomas W. Flaig, Amir Mortazavi
Publikováno v:
J Clin Oncol
PURPOSE The combination of gemcitabine and cisplatin (GC) is a standard therapy for metastatic urothelial carcinoma. Based on data that angiogenesis plays a role in urothelial carcinoma growth and progression, a randomized placebo-controlled trial wa
Autor:
Scott T. Tagawa, Yohann Loriot, Daniel P. Petrylak, Loretta M. Itri, Arjun Vasant Balar, Trishna Goswami, Aude Flechon, Quan Hong, Manojkumar Bupathi, Arash Rezazadeh Kalebasty, Rohit Jain, Petros Grivas, Christos Kyriakopoulos, Philippe Barthélémy, Philippe Beuzeboc, Phillip L. Palmbos, Cora N. Sternberg, Neeraj Agarwal, Damien Pouessel
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(22)
PURPOSE Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited options that offer objective response rates (ORRs) of approximately 10% with a med
Autor:
György Bodoky, Dung Thai, Manish A. Shah, Alexander Starodub, Johanna C. Bendell, Joyce He, David Cunningham, Jaffer A. Ajani, Zev A. Wainberg, Pankaj Bhargava, Desmond Yip
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 39, iss 9
PURPOSE Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9, an extracellular enzyme involved in matrix remodeling, tumor growth, and metastases. A phase I and Ib study of modified oxaliplatin, leucovorin, and fluoro